Berlin, March 22 Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).1 These new EAU guidelines, issued today in Berlin, put Sutent, the first multi-targeted tyrosine kinase inhibitor to be approved in the EU for first-line use in mRCC, at the forefront of drug therapy for this devastating condition.
Sunitinib malate is an oral therapy belonging to a new class of dual-action multi-targeted drugs that attack cancer by inhibiting tumor growth and starving the tumor of blood, thereby reducing its ability to continue to divide and grow.
"There is strong clinical evidence to support the use of sunitinib malate to achieve significantly better progression free survival than was possible with previous standard of care therapy, interferon-alpha (IFNα). The 1st line recommendation of sunitinib malate in the EAU Guidelines is an important step forward in ensuring that this exciting new treatment option becomes a new standard of care in mRCC therapy across Europe", said Prof. Kurt Miller, member of the executive board of the German Working Group for Urological Cancer (AUO) and Head of Department of Urology, Charit Campus Benjamin Franklin, Berlin.
The EAU guidelines are based upon a comprehensive independent evaluation of clinical trial data and other resources relating to the treatment of mRCC, designed to assist urologists in implementing an evidence-based approach in their clinical practices.
"Achieving EAU guideline recognition for Sutent so soon after the EU marketing
authorization for the first line treatment of mRCC demonstrates what an important
treatment option sunitinib malate has already become for physicians
Contact: Alison MacKenzie